Get started
dorfmanmaster

G1 Therapeutics RALLY

Long
G1 Therapeutics, Inc. (NASDAQ:GTHX)  
dorfmanmaster  
NASDAQ:GTHX   G1 Therapeutics, Inc.
Trend Analysis Beyond Technical Analysis Technical Indicators biotechnology biotech PHARMA fda rally analyst Earnings trilaciclib
3
0
trendanalysis beyondta indicator biotechnology biotech pharma fda rally analyst earnings trilaciclib
Earnings/News
  • Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions

  • GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September

  • FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co


Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.